Lilly Makes Billions of Weight-Loss Pills
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...
Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The ...
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently provided insights on. Cramer highlighted it as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback